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Summary 
Human hCG and its -subunit (hCG) are tumour autocrine growth factors whose 
presence in the serum of cancer patients has been linked to poorer prognosis. Previous studies 
have shown that vaccines, which target these molecules and/or the 37 amino acid C-terminal 
hCG peptide (hCGCTP), induce antibody responses in a majority of human recipients. 
Here we explored whether the immunogenicity of vaccines containing an hCG mutant 
(hCGR68E, designed to eliminate cross-reactivity with luteinizing hormone) or hCGCTP 
could be enhanced by coupling the immunogen to different carriers (KLH or Hsp70) using 
different cross-linkers (EDC or GAD) and formulated with different adjuvants (RIBI or 
Montanide ISA720).  
While there was little to choose between KLH and Hsp70 as carriers, their influence on 
the effectiveness of a vaccine containing the BAChCGR68E mutant was less marked, 
presumably because being a foreign species, this mutant protein itself might provide T-helper 
epitopes.  The mutant provided a significantly better vaccine than the hCGCTP peptide 
irrespective of the carrier used, how it was cross-linked to the carrier or which adjuvant was 
used when hCG was the target.  Nonetheless, for use in humans where hCG is a tolerated self-
protein, the need for a carrier is of fundamental importance.  Highest antibody titres were 
obtained by linking the BAChCGR68E to Hsp70 as a carrier by GAD and using RIBI as the 
adjuvant, which also resulted in antibodies with significantly higher affinity than those 
elicited by hCGCTP peptide vaccine. This makes this mutant vaccine a promising candidate 
for therapeutic studies in hCG-positive cancer patients. 
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Introduction 
The pregnancy hormone human chorionic gonadotrophin (hCG) is a member of the 
glycoprotein hormone family. Like the other members of this family, luteinizing hormone 
(LH), follicle stimulating hormone (FSH) and thyroid stimulating hormone (TSH), hCG is a 
heterodimeric molecule consisting of a common -chain non-covalently associated with a 
hormone-specific -chain. Initially, hCG is expressed in the early embryo and is required for 
implantation into the uterus [1]. Subsequently, synthesis shifts to the placental trophoblast 
where it stimulates the corpus luteum to produce progesterone and estrogen to ensure its 
maintenance for the duration of the pregnancy. The pioneering studies of Talwar and 
colleagues have shown that antibody-mediated bioneutralization of hCG in women indeed 
prevents pregnancy [2, 3].  
Highly sensitive assays have identified very low levels of hCG or hCG expression 
in normal tissues of both men and non-pregnant women, but the function of these hormones 
in this context has still to be elucidated [4]. hCG is also a biomarker for the detection of 
patients with placental and trophoblast-derived cancers and  patients with germ-cell derived 
tumours. Importantly, the hormone-specific -subunit hCG has been associated with a wide 
range of epithelial tumours ranging from bladder, lung, oral/facial, breast, cervical, ovarian, 
vaginal, prostate, renal and pancreatic carcinomas [5-7]. Although the full biological role of 
hCG in these cancers is still being elucidated, model systems have shown that hCG is 
necessary for survival of the bladder cancer SCaBER [7] and the cervical cancer HeLa [8] 
cell lines  In these systems hCG may be functioning as an anti-apoptotic growth factor [8-
10]. Furthermore, high titres of hCG-specific antibody prevented the growth of an hCG-
expressing hepatoma H22 cell line xeno-grafted into mice [11]. This latter study showed also 
that the induced anti-hCG antibodies significantly reduced angiogenesis in the H22 grafts. 
There is also evidence to implicate hCG in metastasis and invasion of cancer cells through 
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down regulation of E-cadherin [12], which normally prevents invasiveness of carcinoma cells 
[13]. In 2010, a review of the 43 papers that listed hCG as a cancer biomarker, identified 20 
(47%) where the expression of hCG was associated with poor prognosis and accelerated 
death [6].  It would seem logical therefore, that bioneutralization of hCG in these cancers 
could improve the survival of cancer patients thus identifying the subunit as an important 
target for anti-cancer therapy.  
hCG is a structurally and immunologically well-characterized molecule. The crystal 
structure has shown it to be a member of the cysteine-knot superfamily of growth factors 
[ 14,15].  The use of competitive immunoassays [16-21] and amino acid substitutions [22,23] 
have identified sixteen immunological regions on hCG of which five epitopes have been 
mapped on the -subunit, seven identified on the -subunit and four epitope clusters located 
on the interface between the - and -chains. The hormone specific -subunit of hLH shares 
85 % of the amino acid sequence with the first 110 amino acid residues in hCG which 
accounts for the dominant immune epitopes on hCG being shared with LH so that hCG-
induced antibodies may cross-react with LH [23];  it is also likely that many of the T-cell 
epitopes will be shared with LH.  
 With the aim of neutralizing the role of hCG in pregnancy, Talwar and his group 
developed a heterospecies hCG anti-fertility vaccine consisting of an ovine - and human -
subunit conjugated to tetanus or diphtheria toxoid. In a ground-breaking human phase II trial 
with this vaccine they found only one pregnancy in 1224 cycles in the immunized women 
who produced anti-hCG antibodies levels above 50 ng/ml [3]. The effect of the vaccine was 
reversible because pregnancies were detected whenever the hCG antibody levels fell below 
the protective threshold [2,3].  Although, to our knowledge, the use of this vaccine has not 
been pursued further, it nevertheless demonstrates that it is possible to develop 
bioneutralizing hCG vaccines in humans and indeed, in the last two decades, hCG has been 
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examined as a target for anti-cancer vaccines. However, the heterospecies vaccine protected 
only 80% of the immunized women in this trial who produced the bioneutralizing levels of 
anti-hCG antibodies. The need for enhanced immunogenicity was recognized by Talwar, 
leading to his development of new formulations including the use of E.coli endotoxin and 
killed mycobacteria to boost the immune response [24]. We have previously shown that 
immunization with a GnRH analogue conjugated to mycobacterial hsp70 as a carrier reduced 
the fertility of male mice [25] 
 Stevens promoted the use of the 37 amino acid C-terminal segment of 
hCGhCGCTP), not present in LH as a possible hCG-specific vaccine candidate [26]. 
Indeed, in a human phase I trial involving 37 patients with recurrent or metastatic tumours, 
Triozzi et al showed that synthetic hCGCTP covalently attached to diphtheria toxoid 
induced hCG-specific antibodies at levels between 0.1-2 g IgG per ml (1-20 nM) in a dose-
dependent manner [27,28]. The effect of the vaccine on the tumours was not evaluated 
although Triozzi et al noted that two patients with colorectal cancers showed tumour 
regression [28]. They did not, however, assess whether this was due to the induced hCG-
binding antibodies or because of their observation that the carrier and adjuvant induced strong 
Th1 as well as Th2 cytokine responses in all patients. However, we consider that the C-
terminal segment is not an ideal immunological target for two reasons. First, it contains four 
0-linked glycosylation sites, which are occupied in native hCG and its free hCGsubunit so 
that the carbohydrate chains could physically block or mask some of the potential B-cell 
epitopes in the C-terminal segment. Secondly, it is a highly flexible molecule with no fixed 
structure and is thus entropy-rich, making it a poor immunogen favoring the production of 
antibodies with low affinity for the hCG target. In another approach to overcome the poor 
immunogenicity of hCGCTP, Xiangbing et al. constructed a fusion protein consisting of 
heat shock protein (Hsp65) with ten tandem repeats of hCG109-118 and a copy of 
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hCG109-145 peptide.  This vaccine was able to suppress the growth of mouse hepatoma 
H22 cells in mice [11], but it remains to be seen whether it will be able to induce 
bioneutralizing responses in an outbred populations like humans with their diverse HLA 
haplotypes.  
We have previously reported an alternative hCG vaccine candidate consisting of 
hCG with a single amino residue substitution (R68E) and which has minimal LH-cross-
reactivity [23,29,31].  We showed that the entropy-rich C-terminal segment becomes 
electrostatically fixed through the interaction between the Glu68 residue and the lysine and 
arginine residues in the C-terminal segments. This directs the immune response towards 
hCG-specific epitopes, including those in the C-terminus of the -subunit, in both rabbits 
and mice using both conventional protein as well as DNA immunization [23, 29-31].  
The present study evaluates whether our mutant is a more potent hCG-specific 
vaccine candidate than hCGCTP, whilst at the same time addressing the concerns regarding 
LH-cross reactivity raised in the Talwar hCG trials [3]. We have also sought to improve the 
immunogenicity of hCGCTP and hCGR68E by covalent coupling to either Hsp70 or 
keyhole limpet haemocyanin (KLH) and evaluated two oil-in-water adjuvant systems RIBI 
and Montanide ISA72. We report here that our mutant hCGR68E is superior to CTP as a 
vaccine candidate.  
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Material and Methods 
Reagents 
Recombinant hCG produced in CHO cells was purchased from Sigma-Aldrich 
(UK); Recombinant BAChCGR68E was purified from baculovirus-infected HiFive insect 
cells (see below). The C-terminal peptide (hCGCTP) representing the amino acid residues 
108-145 of hCG was synthesized in vitro and kindly provided by Professor Vernon C 
Stevens, Ohio State University, Columbus, OH or synthesized in house. Recombinant 
endotoxin-free Hsp70 was a gift from Professor Theo Verrips, Utrecht University, and KLH 
was purchased from Sigma-Aldrich (IL).  The CTP-specific mAbs used in the study were 
OT3A2 (kindly provided by Dr E Bos, NV Organon, Oss, The Netherlands) and 2F4/3 
(Sigma-Aldrich). The carrier –specific antibodies used were rabbit anti-KLH IgG (Sigma-
Aldrich) and rabbit anti-Hsp70 antiserum kindly provided by Professor Theo Verrips.  
 
Production and purification of baculovirus-produced hCG-R68E  
The pBAC2hCGR68E baculovirus expression plasmid for production of 
recombinant hCGR68E with a C-terminal His6-tag [29] was transiently introduced into 
HiFive insect cells (InVitrogen) and a single recombinant virus expressing BAChCGR68E 
was isolated and expanded. For large scale production of the recombinant protein the insect 
cells were grown in roller flasks in Express Five medium ((InVitrogen) supplemented with 
1% penicillin/streptomycin and 16 mM L-glutamine to a density of 1.5x105 cells per ml at 
28oC. The cells were infected with the recombinant baculovirus using a multiplicity of 
infection (MOI) of 10 and the supernatant harvested 72 hr post infection, centrifuged and 
immediately stored at -70oC. Recombinant BAChCGR68E was affinity purified in batches 
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of 50-200 ml insect cell supernatants after dilution with an equal volume of 20 mM Na2HPO4, 
0.5 M NaCl pH 7.3 containing protease inhibitors (Sigma-Aldrich).  The BAChCGR68E 
was then centrifuged at 5000 rpm, filtered through a 0.45  filter, and loaded onto HiTrap 
columns according to the manufactures’ instructions (GE Healthcare Life Sciences) using a 
HPLC system using a flow rate of 1 ml/min. After extensive washing with 20 mM Na2HPO4, 
0.5 M NaCl pH 7.3 followed by 20 mM Na2HPO4, 0.5 M NaCl, 25 mM imidazole pH 7.3, the 
recombinant protein was eluted with 20 mM Na2HPO4, 0.5 M NaCl, 400 mM imidazole pH 
7.3 and concentrated to 0.65-1.0 ml using Centricon YM-10 columns (Millipore) centrifuged 
at 5000 rpm. One l of the initial supernatant and purified samples were separated on a 12.5% 
SDS-PAGE using Phast System (GE Healthcare Life Sciences), silver stained and transferred 
to nitrocellulose membrane. Immunoblot analysis was carried out using hCG-specific 
monoclonal antibodies and a 3,3’-diaminobenzidine (DAB) enhanced liquid substrate System 
tetrahydrochloride for chromogenic detection (Sigma).   
 
Coupling of CTP and hCG-R68E to carrier proteins  
The recombinant proteins were conjugated to Hsp70 and KLH using either 
glutaraldehyde (GAD) (Sigma-Aldrich UK) or 1-ethyl-3(3-dimethylaminopropyl)carboiimide 
(EDC) (Pierce UK) using a two-step coupling procedure. For coupling with GAD, synthetic 
hCGCTP (0.75 mg) or BAChCGR68E (1 mg) was incubated with 0.075% GAD for 2 hr at 
4oC with gentle rotation followed by desalting using a PD10 column (Pharmacia). For cross-
linking with EDC, the two-step protocol recommended by the manufacturer was followed. In 
brief, hCGCTP (0.75 mg) or hCG-R68E (1 mg) was dialyzed into 0.1M 2-(N-
morpholino)ethanesulphonic acid (MES), 0.5M NaCl, pH 6.0, incubated with 2 mg of EDC 
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for 15 min at RT, de-salted using a PD10 column and then added to an equal volume of 
Hsp70 or KLH in PBS and incubated at room temperature (RT) for 2 hr with gentle rotation.  
The success of conjugation to Hsp70 was examined using analytical HPLC gel 
filtration, SDS gel electrophoresis and Western blotting using PhastSystem and highly 
sensitive sandwich ELISA using antibodies to the carriers and monoclonal CTP-specific 
OT3A2 mAb which recognises the amino acids 133-139. The molar coupling efficiency 
(number of antigen molecules per mole of carrier) was estimated by determining the amino 
acid composition of the final Hsp70-hCGCTP and Hsp70-BAChCGR68E conjugates and 
calculating the molar concentration of the antigens using selected amino acid residues. The 
KLH-conjugate was too large for this analysis. 
 
Immunisation of mice 
Six-week old female BALB/c mice (Harlan Olac, Bicester UK) were kept according 
to UK Home Office guidelines and the experimental procedures were covered by Home 
Office Animal Project guidelines. The animals used were primed with a 10 g aliquot of the 
Hsp70- or KLH-conjugate containing hCGCTP or BAChCGR68E in RIBI (Sigma-Aldrich 
UK) or Montanide ISA720 (SEPPIC, Paris, France) followed by a boost 21 days later. Two 
weeks after the boost, the animals were exsanguinated and the serum antibodies titered using 
direct binding ELISA. For this, Nunc MaxisorpC 96 well flat-bottomed microtitre plates were 
coated at 4oC overnight with 50 l recombinant hCG (Sigma-Aldrich UK), hCG, or 
ovalbumin at 1 g/ml or hCGCTP peptide at 5 g/ml in 50 mM carbonate-bicarbonate 
buffer (CBB) pH 9.6. After washing the plates extensively with PBS they were blocked with 
2% w/v bovine serum albumin (BSA) in PBS for 30 min at RT followed by washes with PBS. 
The sera were serially diluted in PBS, 0.05% Tween 20, 1% BSA and 50 l was added to 
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each well and incubated for 2 h at 37oC. The plates were washed extensively with PBS, 
incubated with horseradish peroxidase-conjugated goat anti-mouse IgG or subclass-specific 
IgG (Sigma-Aldrich UK) for 1 h at 37oC, washed and developed with 50 l 
tetramethylbenzidine (TMB) and read at A630 using an ELISA plate reader.  The avidity was 
determined using ELISA essentially as described above using antiserum at a concentration of  
80% of the plateau binding followed by an incubation of the antibody-antigen complexes with 
increasing concentration of (0.031 M – 8M) ammonium thiocyanate for 15 min at RT [33].  
The plates were subsequently washes and developed using horseradish peroxidase-conjugated 
goat anti-mouse IgG as described above. 50% inhibition of the ammonium thiocyanate 
concentration was determined as the avidity index.  
 
Statistical analysis 
A 10 point standard curve of antiserum dilution against signal (absorbance) was 
constructed for each antiserum produced from each mouse using a 4 parameter Logistic 
Curve Fitting (elisa analysis.com). The highest dilution that could be distinguished from the 
blank (mean absorbance + 2SD from ovalbumin-immunized mice) was recorded as an index 
of immunogenic vaccine potency.  The independent effects of different carriers, linkers and 
adjuvants on the titre were analyzed using general linear model multivariate analysis of 
variance with a hierarchical design and Tukey’s HSD post hoc analysis. A student t-test was 
used for the isotype and avidity analysis. 
12 
 
Results 
Characterization of conjugates  
Affinity-purified BAChCGR68E with a molecular weight of 25 kDa is smaller than 
the 45 kDa CHO-produced hCG (Figure 1A) due to differences in the structural complexity 
of the carbohydrate chains but not the diminished degree of glycosylation [34]. As reported 
previously, baculovirus-produced recombinant wild-type and mutant hCGsubunit fold 
correctly as judged by their full recognition of a panel of conformation-dependent monoclonal 
antibodies [30].  Once purified, BAChCGR68E as well as synthetic hCGCTP were 
chemically coupled to Hsp70 and to KLH using GAD, which we had used previously to 
chemically attach GnRH to Hsp70 [25], as well as the zero-length crosslinker, EDC. Western 
blot analysis of the Hsp70-based conjugates shows covalent attachment of the immunogens to 
the carrier (Figure 1B). We estimated the relative molar conjugation ratio of 
hCGR68E:Hsp70 and hCGCTP:Hsp70 as 4.7:1 and 31:1, respectively, by determining the 
increase in the molar content of tyrosine and valine, respectively, in a full amino acid 
quantification of conjugates relative to the native Hsp70 (Figure 1C). It was not possible to 
get a meaningful estimate of the coupling efficiency of BAChCGR68E and hCGCTP to 
KLH due to its very large molecular weight of 7.8x103 kDa.  
 
Immunogenicity of hCBR68E versus hCGCTP 
The immunogen-carrier complexes were used to immunize groups of female BALB/c 
mice with two different oil-in-water adjuvants, RIBI and Montanide ISA720, chosen because 
they have both been approved for human use (Table 1). The specificity of the elicited 
antibodies was characterized using endpoint titration ELISAs against the target antigens hCG, 
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hCG and hCGCTP and using ovalbumin as the negative control. The dilutions representing 
the highest dilution that could be distinguished from the mean absorbance plus 2SD of 
ovalbumin were recorded (Figure 2). There was no significant difference between the results 
obtained with intact hCG and with the recombinant hCGβ when used as target antigens. We 
therefore combined the results obtained with these two antigens in our statistical analysis.  
Given that both BAChCGR68E and hCGCTP produced immune-responses that are likely 
to be effectively devoid of LH crossreactivity, our first question was: which is the better 
immunogen? When targeting hCG/hCG the BAChCGR68E antisera showed better 
binding to the antigens than the antisera elicited with hCGCTP (for BAChCGR68E mean 
titre was 1:26500; for hCGCTP mean titre was 1:12600, p<0.0001) (Table 2, Figure 3). 
Even when titered against the synthetic hCGCTP peptide as the target antigen, we found that 
the baculovirus-derived recombinant protein elicited more potent immune response than that 
observed with hCGCTP conjugates as immunogens (BAChCGR68E mean titre 1 in 
210800, hCGCTP mean titre 1 in 54500, p=0.039; Figure 4, Table 2).  
Enhancing the immunogenicity 
In the reported phase II trial with the hetero-CG vaccine, a substantial fraction 
(~20%) of the immunized women failed to develop protective immunity [24]. One likely 
explanation could be that the vaccine-formulation used was suboptimal for this group of 
recipients for genetic and/or immunological reasons. It is therefore possible that the number 
of poor responders could be reduced by using a vaccine with greater immunological potency. 
We decided therefore to explore the effect of different immunological carriers, chemical 
linkers and adjuvant systems on immunogenicity.  No statistical differences were observed 
between Hsp70 and KLH as carriers irrespective of the immunogen (BAChCGR68E versus 
hCGCTP) or linker (GAD versus EDC) (Figure 3).  
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When considering the adjuvant system (RIBI versus Montanide ISA720) the 
BAChCGR68E immunogen elicited no statistical difference in the antibody titres 
irrespective of the adjuvant, linkers or antigen targets used with the one exception of RIBI 
being the superior adjuvant with the hCGCTP target (Figure 3).  However, the CTP-vaccine 
did reveal differences. When titered on its biological target hCG/hCG the CTP-immunogen 
formulated with RIBI produced significantly higher titre antibodies than those obtained using 
the Montanide ISA720-formulation but only when the synthetic peptide had been crosslinked 
to its carrier with GAD (mean titre RIBI 1:15000, Montanide ISA720 1:2000, t-test p<0.05). 
When titered against the synthetic hCGCTP peptide itself, the antisera generated with RIBI 
elicited significantly higher antibody responses than immunogen adjuvanted with Montanide 
ISA720 irrespective of the linker (p<0.001) (Figure 3).  
Combining all the antibody responses to the mutant recombinant BAChCGR68E 
revealed no differences in the overall potency of the two adjuvants with respect to affinity 
(Figure 5A). However, as shown in Figure 5B and 5C the BAChCGR68E-elicit antibodies 
binding to hCGCTP with lower avidity than to hCG but with the same avidity as hCGCTP-
induced antibodies independent of the carrier.  For the analysis we used an avidity index 
defined as the concentration of ammonium thiocyanate required to dissociate 50% of the 
antigen-antibody complexes as indicated in Figure 5B. Using this index it can be seen that 
there were no statistical differences in the affinity of the specific antibodies produced by the 
hCGCTP immunogens and independent of the carrier when binding to hCGCTP. In 
contrast, hCGCTP-specific antibodies from hCGCTP-HSP70 immunised mice bound to 
the synthetic peptide with significant lower affinities (p,0.007) (Figure 5C). We have 
previously shown that the amino acid substitution in BAChCGR68E fixed the C-terminal 
part of hCG through electrostatic interaction this masking the immunodominant LH-cross-
reactive epitope on hCGbut enhances a hCGCTP-specific epitope [29-31]. It is therefore 
15 
 
not surprising that the avidity of the hCGCTP-specific antibodies were comparable to that 
induced by hCGCTP-immunogens and higher than hCGCTP antibodies induced by 
hCG . In addition, the antibodies induced with at the BAChCGR68E 
immunogen had a significantly greater affinity overall than antibodies induced by hCG 
Surprisingly IgG2a and 2b titres were significantly lower with Montanide ISA720 than with 
the RIBI formulations (Figure 6).  
 
Our results revealed a clear difference between the immunogens. Collectively, the 
BAChCGR68E vaccine formulation gave significantly greater responses against both targets 
than did the hCGCTP-based vaccines (Figure 3).  Using hCG as target, the hCGCTP linked 
to carrier by GAD with RIBI adjuvant gave the best antibody response of the hCGCTP 
immunogen group but this was significantly lower than the corresponding result with the 
BAChCGR68E mutant (p<0.014). 
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Discussion 
Human CG has traditionally been associated with pregnancy, but the recent decades 
have revealed that hCG and hCG are also biomarkers for trophoblastic and epithelial cancers 
and the presence of hCG is predictive for poor survival of patients (recently reviewed in [6]) 
possibly because it prevents apoptosis or functions as a cancer growth factor. Phase I/II trials 
of an antifertility vaccine, based on a heterodimeric CG molecule, by Talwar and his group 
showed that it is possible to break immunological tolerance to hCG and thereby elicit 
sufficient levels of antibodies to prevent pregnancy in immunized women [3]. hCG has 
therefore subsequently been considered as a potential immunotherapeutic anti-cancer vaccine 
candidate [10,11].  
Morse et al. and Celldex Therapeutics Inc have recently explored an hCG-targeting 
bladder carcinoma vaccine with a formulation that induced T- as well as B-cell mediated 
immune responses. It consisted of a fusion protein where the human monoclonal anti-
mannose receptor antibody B11 was extended with hCG at the C-terminus (CDX-1307).  In 
a phase II trial, CDX-1307 was given with GM-CSF and Toll-like receptor 3 and 7/8 agonists 
known to enhance the adaptive immune response as well as Cisplatin and Gemcitabine for 
broader cancer cell targeting [32, 35]. The phase II trial was discontinued after fourteen 
months due to difficulties in recruiting sufficient number of patients (RK Iles, personal 
communication). We have argued here that an hCGbased vaccine will produce 
predominantly LH-cross reactive antibodies due to the immune dominance of the shared 
epitopes. We presume furthermore that the 85% sequence homology between the hormone-
specific subunit of LH and the first 110 amino acids of hCG indicates that the two hormones 
also share most of the MHC class I epitopes.  Although it is possible that such LH cross-
reactivity in both arms of the adaptive immune system may not be of immediate concern for 
cancer patients, we do argue for hCG-specific vaccines that predominantly target the 
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antibody-mediated arm of the immune system to avoid undesirable long-term complications. 
Most efforts have been focused on the unique C-terminal peptide of hCG. AVI BioPharma 
Inc has taken a vaccine consisting of hCGCTP37 coupled to diphtheria toxoid (CTP37-DT) 
through phase I with patients with a number of different epithelial cancers followed by a 
phase II trials in 77 patients of metastisizing colorectal carcinomas. However, the vaccine-
induced hCGCTP antibodies were not able to neutralize the tumour-derived hCG either 
due to the high entropy of C-terminal segment or because the hCGCTP antibodies were of 
low affinity.  It is therefore not clear whether the effect in the high responders was related to 
induction of hCG-specific antibodies or to general stimulation of the immune system by the 
DT carrier, which elicited a systemic cytokine response [27]. It is, furthermore, possible that a 
better protection could be achieved in patients with hCG-producing cancers.  
We show here that our hCGR68E mutant may be a more suitable immunogen than 
either hCG or hCGCTP. The Glu68 mutation fixes the CTP via salt bridges to its positive 
amino acids thereby not only blocking the immunodominant LH cross-reactive epitopes but  
creating also a novel dominant CTP B-cell epitope possibly located at the novel loop and 
including the amino acid residues 105-120 [28-30]. BAChCGR68E conjugated to either 
Hsp70 or KLH produced significantly higher levels of immune reactive hCG antibodies than 
hCGCTP-Hsp70 or hCGCTP-KLH irrespective whether they were titered against hCG, 
hCG or CTP. However, the difference in the antibody levels was not as pronounced when 
tittered against CTP. There may be several reasons for this. The molar level of CTP per 
Hsp70 molecule was 6.6 times higher than for BAChCGR68E per Hsp70. In addition, the 
CTP, was a synthetic peptide with at least four known B-cell epitopes some of which may be 
masked by the four 0-linked carbohydrate residues present in the C-terminal part of 
BAChCGR68E. One would therefore expect that not all of the antibody specificities elicited 
with hCGCTP formulation, would recognize hCG/hCG.  
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As with the anti-fertility trial of Talwar and colleagues [3], the CTP37-DT vaccine 
identified a significant group of non-responders [27]. The molecular basis for the inability of 
20% of the individuals participating in two trials who failed to respond to the vaccines 
remains to be elucidated. It is possible that there are genetic reasons for this since  the two 
trials included diverse ethnic patients. However, all patients included in the two trials 
responded normally to the carrier, demonstrating a functional immune response. Since 
Moulton et al. reported that detectable levels of anti-hCG antibodies were only seen after the 
second boosting [27], it is possible that enhancing the immunogenicity of the immunogen or 
vaccine formulation or repeated boosting may reduce the number of non-responders. We 
explored whether we could enhance the immunogenicity of BAChCGR68E or hCGCTP by 
coupling the vaccine candidate to different carriers, using different cross-linkers or 
formulating them with different adjuvants. Whilst these different constructs induced a modest 
but statistically significant increase in the immunogenicity of hCGCTP, these improvements 
were less pronounced with BAChCGR68E. Nonetheless, even by enhancing the 
immunogenicity, the hCGCTP vaccine formulation was not as potent as our mutant 
molecule. Differences in ability of the antisera to neutralize circulating hCG may be even 
greater if, as we expect, the high entropy unconstrained CTP immunogen produces a low 
affinity response. While as mentioned, the effect of conjugation with carrier was relatively 
modest, perhaps because hCG is a foreign molecule for mice, for human use the involvement 
of carrier protein would be essential since hCG is a tolerated self-protein. Although the 2 
adjuvants did not induce antibodies with overall differences in avidity as revealed by 
ammonium thiocyanate dissociation, the superiority of RIBI with respect to IgG subclass 
response and induction of the highest antibody titres emphasize the need for careful attention 
that needs to be paid to the choice of adjuvant for a vaccine intended for human use. The 
avidity analysis revealed that when tested on hCGCTP peptide-coated plates the antibodies 
elicited by hCGCTP and BAChCGR68E immunogens had the same avidity, which was 
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significant (p<0.007 in student t-test) than hCGCTP-specific antibodies induced by hCG 
conjugated to the same carrier. However, the affinities of the antibodies produced in 
hCGCTP-immunized mice were significantly lower when assayed on plates coated with 
hCG. This reflects probably more an assay artifact because coating of the CTP peptide will 
anchor it in a fixed low-entropy conformation. When hCG is coated to the plastic of the 96 
well plates the CTP will not all be immobilized the plastic thus having no fixed conformation 
and be very entropy rich which will reduce the availability of the right binding conformation 
for the induced antibodies. In addition, maybe the molar concentration of hCGCTP peptide 
is higher in the peptide-coated plates.  What the avidity data clearly demonstrated is that the 
avidity of hCG-specific antibodies produced by our mutant immunogen were significantly 
higher than the antigen-specific antibodies produced by either hCGCTP or hCG 
immunogens. This makes BAChCGR68E a much better vaccine candidate. 
In conclusion, we have compared two hCG-specific vaccine candidates hCGCTP 
and BAChCGR68E delivered using different formulations and report here that the hCG 
mutant BAChCGR68E is a significantly more potent (or effective) vaccine than hCGCTP 
irrespective of the carrier used, how it was crosslinked to the carrier or which adjuvant system 
used. Highest antibody titres were obtained by linking the AChCGR68E to Hsp70 as a 
carrier by GAD and using RIBI as the adjuvant, and although we do not know whether it will 
be a superior vaccine that can reduce the fraction of non-responders identified in the phase II 
trials of hCG vaccines so far, the increased immunogenicity relative to hCGCTP looks 
promising. 
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Figure Legends 
 
Figure 1.  Purification of BAChCGR68E and coupling of the immunogens to 
carrier proteins. (A) 1 l of affinity purified recombinant BAChCGR68E was separated by 
12% SDS PAGE followed by Western blotting and compared to CHO-produced hCG: Lanes 
1-3 show rhCG at 0.25, 0.5 and 1.0 mg/ml and Lane 4-5 show two batch batches of purified 
BAChCGR68E preparations. (B) Western blot analysis using the OT3A2 mAb showing the 
coupling of hCGCTP and BAChCGR68E to Hsp70; Lane 1 hCGCTP; Lane 2 Hsp70; 
Lane 3 hCGCTP-Hsp70 conjugated with EDC; Lane 4 hCGCTP mixed with Hsp70; Lane 
5 hCGCTP; Lane 6 hCGCTP-Hsp70 conjugated with GAD; Lane 7 BAChCGR68E-
Hsp70 conjugated with EDC, and Lane 8 BAChCGR68E-Hsp70 conjugated with GAD. (C)  
Evaluation of ratio of hCGCTP:Hsp70 and BAChCGR68E:Hsp70 calculated from total 
amino acid quantification of the conjugates and Hsp70. 
 
Figure 2  Titration of mouse immune sera. The sera from mice immunized with 
either hCGCTP- or BAChCGR68E-conjugate were endpoint titered using direct ELISAs 
on plates coated with hCG (to the left) and the synthetic hCGCTP peptide (to the right). The 
graphs used data that includes both linkers, both carriers and both adjuvants. They show the 
mean absorbance and ±2SD indicated as bars through each data point. The non-specific 
binding of the sera was determined using plates coated with ovalbumin (Ova).  
 
Figure 3  Statistical analysis of the endpoint titration of the sera from BALB/c 
mice immunized with hCGCTP- or BAChCGR68E-conjugates titered on hCGCTP (upper 
diagram) or hCG/hCG (lower diagram). The log10 dilution of the endpoints for the relevant 
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groups are shown using box-and-whisker diagrams where the median is indicated with a 
horizontal bar, the 1QR by a box, the whisker represents the range of data and the mean and 
2SD of the log transformed data. Dilution end points were defined as the highest dilution that 
could be distinguished from the blank (mean absorbance + 2SD from ovalbumin-immunized 
mice). * Denotes significance between BAChCGR68E immunogen compared to the 
hCGCTP immunogen (p<0.05). + Indicates the significant difference in titres between the 
adjuvant RIBI and Montenide ISA720 (p<0.05). * Indicates significant differences compared 
to hCGCTP immunogen with all other conditions the same. 
Figure 4  Statistical analysis of the antibody response to BAChCGR68E 
immunogen generated as a free subunit or used when conjugated to Hsp70 or KLH all 
combined with the adjuvant.  
Figure 5   Avidity of sera from the mice immunised with a BAChCGR68E 
immunogen using the adjuvant RIBI and Montenide ISA720 adjuvant formulations produce 
antibodies with as identical ammonium thiocyanate dissociation when tittered on 
hCGp<0.0021 and **p<0.0019 Student t-test)However, the dissociation of the 
antigen-antibody complexes in sera from mice immunised with BAChCGR68E-HSP70 
immunogen using the adjuvant RIBI tittered on hCG (squares) and CTP (triangles) was 
different. We define an avidity index as the concentration of ammonium thiocyanide that 
results in dissociation of 50% of the antibody-antigen complex (indicated by the stippled 
lines). (C) The relative avidity indexes represented by 50% inhibitory concentrations of 
antibodies rose to constructs for CTP (dark) and hCGß (light). Student t-test was used to 
determine the statistical significance as indicated). 
Figure 6   IgG subclass responses in mice immunised with the BAChCGR68E 
immunogen using the RIBI and Montenide ISA720 adjuvant formulations and tittered on 
hCG  
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